+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Erythropoietin Stimulating Agent Market: By Type; By Disease Cured & By Geography - Forecast 2016-2021

  • ID: 3973916
  • Report
  • March 2016
  • 158 pages
  • IndustryARC
1 of 3
Erythropoietin is a hormone released the human renal system (kidney) which increases the rate of production of red blood cells in response to falling levels of oxygen in the tissues and helps in the process of erythropoiesis (production of red blood cells). Erythropoietin stimulating agents (EPO) are used to treat people undergone chemotherapy or treatments related to HIV. Globally demand for Erythropoietin drugs (EPO) is driven by increasing population with HIV, Cancer and Renal diseases.

This report identifies the erythropoietin stimulating agents market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to erythropoietin stimulating agents market.

Globally North America dominated the market for erythropoietin stimulating agents in 2015 with higher awareness about erythropoietin drugs and higher cases of the renal, oncological and anaemic diseases. However, by 2021 Europe, which closely followed North America as second largest regional market for erythropoietin stimulating agents is expected overcome North America to dominate global market. However, Asia-Pacific market for erythropoietin stimulating agents is expected to post strong growth during the period of study due to increasing purchasing power, rapid development in infrastructure, growing medical tourism, and expansion in available treatments.

This report on global erythropoietin stimulating agents also covers different type erythropoietin stimulating agents, diseases cured and market size in various geographical regions.

The report covers major type of erythropoietin stimulating agents, some of the major types available are as follows: Epoetin-alfa, Epoetin-beta, Epoetin-omega,Epoetin-delta and Darbepoetin-alfa
On the basis of disease cured with the help of erythropoietin drugs, this report on global erythropoietin stimulating agents market is segmented as below covering all major disease cured: Oncology diseases, Kidney Disorders (End stage renal disease (ESRD) and Dialysis), Anemia, Neural Disease and Wound healing
This report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for erythropoietin stimulating agents in each of the region.

This report identifies all the major companies operating in the global erythropoietin stimulating agents market. Some of the major companies’ profiles in detail are as follows:

Teva Pharmaceutical Industries Ltd.

Ranbaxy Laboratories Ltd.

Intas Pharmaceuticals
Biocon Limited
LG Life Sciences Ltd.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Erythropoietin Stimulating Agent – Market Overview

2. Executive Summary

3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis

4. Erythropoietin Stimulating Agent – Market Forces
4.1. Drivers
4.1.1. Globally increasing cases of HIV, Cancer and Renal diseases
4.2. Restraints
4.2.1. Higher cost and duration of EPO therapeutics
4.3. Opportunities
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Erythropoietin Stimulating Agent – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Global Erythropoietin Stimulating Agent Market, By Product Type
6.1. Epoetin-alfa
6.2. Epoetin-beta
6.3. Epoetin-omega
6.4. Epoetin-delta
6.5. Darbepoetin-alfa

7. Global Erythropoietin Stimulating Agent Market, By Disease Cured
7.1. Oncology diseases
7.2. Kidney Disorders
7.2.1. End stage renal disease (ESRD)
7.2.2. Dialysis
7.3. Anemia
7.4. Neural Disease
7.5. Wound healing

8. Global Erythropoietin Stimulating Agent Market, By Geography
8.1. Europe
8.1.1. Germany
8.1.2. France
8.1.3. Italy
8.1.4. Spain
8.1.5. Russia
8.1.6. U.K.
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.1. China
8.2.2. India
8.2.3. Japan
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.3.1. U.S.
8.3.2. Canada
8.3.3. Mexico
8.4. Rest of the World (RoW)
8.4.1. Brazil
8.4.2. Rest of RoW

9. Erythropoietin Stimulating Agent – Market Entropy
9.1. Expansion
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract

10. Company Profiles
10.1. Teva Pharmaceutical Industries Ltd.
10.1.1. Introduction
10.1.2. Financials
10.1.3. Key Insights
10.1.4. Key Strategy
10.1.5. Product Portfolio
10.1.6. SWOT Analysis
10.2. Ranbaxy Laboratories Ltd.
10.2.1. Introduction
10.2.2. Financials
10.2.3. Key Insights
10.2.4. Key Strategy
10.2.5. Product Portfolio
10.2.6. SWOT Analysis
10.3. Intas Pharmaceuticals
10.3.1. Introduction
10.3.2. Financials
10.3.3. Key Insights
10.3.4. Key Strategy
10.3.5. Product Portfolio
10.3.6. SWOT Analysis
10.4. Biocon Limited
10.4.1. Introduction
10.4.2. Financials
10.4.3. Key Insights
10.4.4. Key Strategy
10.4.5. Product Portfolio
10.4.6. SWOT Analysis
10.5. LG Life Sciences Ltd.
10.5.1. Introduction
10.5.2. Financials
10.5.3. Key Insights
10.5.4. Key Strategy
10.5.5. Product Portfolio
10.5.6. SWOT Analysis
10.6. Hospira Inc.
10.6.1. Introduction
10.6.2. Financials
10.6.3. Key Insights
10.6.4. Key Strategy
10.6.5. Product Portfolio
10.6.6. SWOT Analysis
10.7. Roche Diagnostics
10.7.1. Introduction
10.7.2. Financials
10.7.3. Key Insights
10.7.4. Key Strategy
10.7.5. Product Portfolio
10.7.6. SWOT Analysis
10.8. Johnson & Johnson
10.8.1. Introduction
10.8.2. Financials
10.8.3. Key Insights
10.8.4. Key Strategy
10.8.5. Product Portfolio
10.8.6. SWOT Analysis
10.9. Amgen Inc.
10.9.1. Introduction
10.9.2. Financials
10.9.3. Key Insights
10.9.4. Key Strategy
10.9.5. Product Portfolio
10.9.6. SWOT Analysis
10.10. Celltrion, Inc
10.10.1. Introduction
10.10.2. Financials
10.10.3. Key Insights
10.10.4. Key Strategy
10.10.5. Product Portfolio
10.10.6. SWOT Analysis
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Expert Insights
Note: Product cover images may vary from those shown
3 of 3


4 of 3